PNPLA3 and metabolic dysfunction-associated steatotic liver disease: The injection of liver-targeted GalNAC-conjugated antisense oligonucleotides (ASO) that mediates Pnpla3 silencing improved all the characteristics of NAFLD in this mouse model, including liver fibrosis 120.